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Abstract
Growing human atherosclerotic plaques show a progressive loss of vascular smooth muscle cells (VSMC) becoming soft and
vulnerable. Lipid loaded-VSMC show impaired vascular repair function and motility due to changes in cytoskeleton proteins
involved in cell-migration. Clinical benefits of statins reducing coronary events have been related to repopulation of
vulnerable plaques with VSMC. Here, we investigated whether HMG-CoA reductase inhibition with rosuvastatin can reverse
the effects induced by atherogenic concentrations of LDL either in the native (nLDL) form or modified by aggregation
(agLDL) on human VSMC motility. Using a model of wound repair, we showed that treatment of human coronary VSMC with
rosuvastatin significantly prevented (and reversed) the inhibitory effect of nLDL and agLDL in the repair of the cell depleted
areas. In addition, rosuvastatin significantly abolished the agLDL-induced dephosphorylation of myosin regulatory light
chain as demonstrated by 2DE-electrophoresis and mass spectrometry. Besides, confocal microscopy showed that
rosuvastatin enhances actin-cytoskeleton reorganization during lipid-loaded-VSMC attachment and spreading. The effects
of rosuvastatin on actin-cytoskeleton dynamics and cell migration were dependent on ROCK-signalling. Furthermore,
rosuvastatin caused a significant increase in RhoA-GTP in the cytosol of VSMC. Taken together, our study demonstrated that
inhibition of HMG-CoA reductase restores the migratory capacity and repair function of VSMC that is impaired by native and
aggregated LDL. This mechanism may contribute to the stabilization of lipid-rich atherosclerotic plaques afforded by statins.
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Introduction
Atherosclerotic lesions with a large lipid-necrotic core and a thin
fibrous cap are the most prone to rupture [1] triggering the acute
ischemic syndromes. Compared with intact caps, those ruptured
are usually thinner, and contain higher amount of infiltrated lipids
and a paucity of smooth muscle cells (VSMC) [2], the only
vascular resident cells that synthesize extracellular matrix compo-
nents required for the tensile strength of the fibrous cap of the
plaques. In asymptomatic silent disease, plaques are healed by
VSMC that accumulate at the sites of rupture, where they secrete
an extracellular matrix rich in glycosaminoglycans and type III
collagen [3–5]. VSMC number is determined by the net effect of
VSMC proliferation, migration, and death or apoptosis. Cell
migration is associated with dynamic remodeling of the actin-
myosin cytoskeleton [6], which is dependent on the phosphory-
lation/dephosphorylation balance of the myosin regulatory light
chain (MRLC) [7–8].
A key pathogenic event in the development of atherosclerosis is
the retention of colloidal atherogenic lipoproteins, primarily low
density lipoprotein (LDL), in the arterial intima. This retention
occurs when LDL bind to the extracellular matrix proteoglycans,
as versican [9–11] that induces LDL aggregation (agLDL) and
leads to dysfunction of the vascular resident cells [12–13]. agLDL
upregulate the expression of low-density lipoprotein receptor-
related protein 1 (LRP1) [14–15], which in turn internalizes
significant amounts of cholesteryl esters from agLDL contributing
to the transformation of VSMC into lipid loaded cells [15–17]. In
previous studies we have demonstrated that agLDL decrease
phosphorylated-MRLC (P-MRLC) levels and impairs migration
and wound repair in VSMC [18–19]. These effects could
contribute to the development of soft-high risk plaques with
decreased VSMC accumulation.
Statins, inhibitors of 3-hydroxy-methylglutaryl coenzyme A
(HMG-CoA) reductase, are widely used cholesterol-lowering drugs
[20–21] that significantly reduce the presentation of cardiovascu-
lar events in patients either with or without previous coronary
heart disease [22–26]. Vascular remodelling and stabilization of
vulnerable plaques are presumed to be major contributors in these
beneficial effects. To this respect, intravascular ultrasound imaging
(IVUS)-end point studies with statins have shown that they reduce
atherosclerotic plaque burden in treated patients [27] and the
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carotid artery plaques of patients treated with simvastatin have
shown that statins reduced the size of the lesions and the thickness
of the arterial wall without changes in the lumen size [28]. Also,
recent clinical studies reported changes in carotid artery
morphology in terms of increasing echogenicity and fibrous tissue
content as an effect of statins [29–33].
Experimental studies using atherosclerotic animal models have
suggested that the plaque-stabilizing effects of statins are related to
an increase in VSMC and collagen content of the plaques [34–36].
Up to now, however, the mechanisms involved in statin-mediated
enrichment and activity of VSMC in atherosclerotic plaques have
not been fully characterized. In the present study, we investigated
the mechanism by which rosuvastatin, a potent statin that has
shown to induce stabilization of vascular lesions [31] and
regression of clinical coronary atherosclerosis [27], rescues the
VSMC migration kinetics and repair capacity that are impaired by
accumulation of LDL.
Materials and Methods
Human coronary vascular SMC culture, LDL preparation,
and cell treatments
Primary VSMC were obtained by the explant technique from
non-atherosclerotic coronary arteries of hearts, obtained from
anonymized patients under heart transplantation surgery at the
Figure 1. Rosuvastatin prevents the inhibitory effect of atherogenic LDL in wound repair by human VSMC. (A) Representative
photomicrographs of VSMC treated without (B, D, F) or with (C, E, G) rosuvastatin in absence (B, C) or presence of nLDL (D, E), or agLDL (F, G) (B)
Quantification of wound regenerated area (#: control; e: nLDL-treated cells;¤: nLDL+rosuvastatin; %: agLDL; &: agLDL+rosuvastatin). (C) Wound
regeneration kinetics (mm
2/hour) of control and LDL-groups treated without/with rosuvastatin (two-way ANOVA for rosuvastatin treatment and
time). Results in B and C shown as mean6SEM (n=6 independent experiments).
doi:10.1371/journal.pone.0038935.g001
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previously [37]. The study was approved by the Institutional
Review Committee on Human studies of the Hospital de la Santa
Creu i Sant Pau (Barcelona, Spain) that conforms to the
Declaration of Helsinki and tissue samples were collected with
written informed consent from the donors.
To investigate the effect of rosuvastatin on LDL-loaded VSMC,
cell monolayers were preincubated with 10 mM rosuvastatin,
concentration that corresponds to the blood level in patients
treated with a high therapeutic-doses (40 mg), for 2 hours prior to
the addition of 100 mg/mL native-LDL or aggregated-LDL
(nLDL, agLDL) and incubated for further 16–24 hours. In a set
of experiments, inhibitors of MLCK (ML9, Sigma), and ROCK
(Y27632, Sigma) were added for the last 2 hours.
For cell migration and immunohistochemical studies during
VSMC wound repair, cells were grown on monolayers to
confluence on glass bottom dishes (WPI, World Precision
Instruments) and a linear wound was induced after the incubation
period with/without rosuvastatin (+/2 inhibitors), in the pres-
ence/absence of LDL. For proteomic and protein expression
studies, treated cells were washed with ice-cold phosphate-buffered
saline (PBS) and harvested in PBS containing 5 mM EDTA and
stored at 280uC, until used.
Human LDL (density 1.019 to 1.063 g/mL) were prepared by
ultracentrifugation from pooled sera of normocholesterolemic
volunteers. agLDL were generated by vortexing LDL (1 mg/mL),
according to the method previously described by Guyton et al
[38]. As largely demonstrated, the vortexing-generated aggregated
LDL (agLDLs) share structural characteristics, size, and electro-
phoretic mobility with the high atherogenic LDL aggregates
retained in atherosclerotic arterial intima due to versican fusion
[14,38–40]. Intracellular lipid-accumulation in VSMC was
Figure 2. Dose-dependent response to rosuvastatin in cell migration of VSMC exposed to LDL. Bar diagram for (A) dose dependent
effect of rosuvastatin (2.5–40 mM) in wound regeneration by VSMC treated without/with agLDL 8 hours after wounding. P,0.01 (Kruskal-Wallis test)
for rosuvastatin dose-response effect and P,0.001 for simvastatin effect (Man-Whitney test) vs agLDL-group. (B and C) VSMC were treated without
or with rosuvastatin (10 mM) since 2 hours before (2 h-pre LDL) or 8 hours after (8 h-post LDL) adding agLDL to the cell culture medium. B: staining
with Herxheimer reagent (Sudan III and Sudan IV) (red colour) as a control for intra-cellular accumulation of lipids. Ø refers to agLDL-VSMC non
treated with rosuvastatin. C: Results shown as mean6SEM (% of wounded area at time 0) refer % of the wound regenerated area 4 and 8 hours after
wounding (n=4 independent experiments); * p,0.05 compared to the agLDL-group (Man-Whitney test).
doi:10.1371/journal.pone.0038935.g002
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(Sudan III and Sudan IV). In all experiments LDL-oxidation
(before and after aggregation) was excluded by measuring
thiobarbituric acid-reactive substances and by a monoclonal
antibody 4E6-based ELISA (Mercodia) [18].
Cell migration and wound repair assay
A double sided scrape-wound was made on confluent VSMC
monolayers, as previously described [18]. Cell migration and
wound repair were analyzed over a period of 12 hours (37uC) on
10% FCS-stimulated cells. Images were taken under a 610 lens,
using an inverted microscope (Leica DMIRE2) attached to a video
SPOT camera (Leica-DFC350FX), on 3 different fields along the
linear scratch covering more than the 95% of the wound. The area
free of cells in each field was calculated using ImageJ software, and
values averaged. Measurements were made at time 0 and during
cell migration (2, 4, 8 and 12 hours). Cell migration and wound
repair were indirectly assessed by measuring the residual cell-
denuded area. Values were expressed as a percentage of the cell-
depleted area at time 0.
Figure 3. Rosuvastatin prevents MRLC dephosphorylation in VSMC exposed to LDL. (A) Representative 2-DE gel of the cytoskeleton/
membrane fraction. Arrows show spots identified as MYL9 (sarcomeric-MRLC), non-sarcomeric-MRLC (MRLC) and alkali-MLC (MLC). Enlarged images
for the proteomic pattern of the non-sarcomeric MRLC isoforms (MRLC-2, spot 1–2 and MRLC-3 spots 3–4). Note that numbers 1–2 and 3–4 denote
double spots with different pI of the non-sarcomeric MRLC isoforms. (B) Bar-diagrams for ratios between the intensity of the spot with lower pI and
the correspondent with higher pI. Results given as mean6SEM (n=3). P values for Man-Whitney test; only shown differences for P,0.05 (C) Western
blot for phosporylated-MRLC (P-MRLC) and total MRLC in extracts of VSMC exposed to agLDL in the presence of different dose of rosuvastatin (2.5–
10 mM). C denotes the control group. Bar diagram represents quantitative values (mean6SEM) of 3 independent experiments. P values for Man-
Whitney test.
doi:10.1371/journal.pone.0038935.g003
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Arrested VSMC were incubated for 24 hours with 10 mM
rosuvastatin and 100 mg/mL nLDL or agLDL in medium
containing 0.5 mCi/mL of [3H]thymidine (Amersham) and cell
proliferation was determined as previously described [41].
Cell adhesion assay
Subconfluent VSMC, treated with/without rosuvastatin in the
presence/absence of agLDL (16 hours), were harvested and
resuspended in 5% FCS-M199 medium. Afterwards, 1610
5 cells
were seeded on FCS-coated glass bottom dishes and further
incubated for 3 hours in the presence/absence agLDL, without/
with rosuvastatin +/2 Y27632. After 3 hours, the attached cells
were fixed with 4% paraformaldehyde for confocal microscopy
studies or released by trypsination, stained with trypan blue for
determination of cell viability and counted in a Neubauer-
chamber. Experiments were performed in replicates and mean
values were calculated.
Protein extraction and proteomic analysis
Frozen cell pellets were sequentially extracted in tris- and urea
buffers to separate the cytosolic and membrane/cytoskeleton-
enriched protein fractions [18]. Total cell lysates were made in
RIPA-buffer. (50 mM Tris HCl pH 8; 150 mM NaCl; 1% NP-40;
0.5% sodium Deoxycholate; 0.1% SDS). Protein concentration
was measured with 2D-Quant Kit (GE-Healthcare), as indicated
by the manufacturer.
For the proteomic analysis, sample contaminants were removed
(2D-CleanUp Kit, Amersham) and proteins (120 mg) separated by
2-dimensional electrophoresis (2-DE) as previously described [18–
19]. Protein spots in the gels were labelled by fluorescence
(Flamingo labelling, BioRad), scanned (Typhoon, GE-Healthcare),
and analysed for differences in the protein patterns between
groups with PD-Quest 8.0.1 software (8.0.1, Bio-Rad) [18–19].
Protein identification was performed by matrix-assisted laser
desorption/ionisation-time of flight (MALDI-ToF) mass spectrom-
etry (Ettan MALDI-ToF Pro, GE Healthcare) as previously
described by our group [18].
Western blot analysis
Protein antigen levels in cytosol and membrane fractions were
analyzed by western blot, as described previously [18–19] using
following primary antibodies: monoclonal anti-MRLC (Abcam,
dilution:1/500), polyclonal anti-phosphorylated-MRLC (Abcam,
dilution:1/500), monoclonal anti-RhoA (Santa Cruz, diution:1/
500), polyclonal anti-p160ROCK (Santa Cruz, dil:1/500), mono-
clonal anti-phosphorylated-PAK1 (Abcam, dilution:1/10000), and
monoclonal anti-b-actin (Abcam, dilution:1/5000). Western blot
bands were detected by chemiluminescence using a peroxidase
enzymatic reaction (Supersignal, Pierce) and quantified with a
Figure 4. Rosuvastatin increases RhoA at the leading edge of migrating cells. Confocal microscopy for RhoA antigen labelling (green) in
migrating cells (FCS-stimulated), 4 hours after the wound scratch. Immunocytology was performed in permeabilized cells. Red signal refers to F-actin
(Alexa-Fluor 633 conjugated phalloidin). (A) Representative photomicrographs of RhoA labelling at the wound-border of control cells and agLDL-
treated cells. (B) Effect of 10 mM rosuvastatin on RhoA localization at the leading-edge of control- and agLDL-VSMC. (C) Bar diagrams show
quantitative levels (mean6SEM) of RhoA labelling over an area 15 mm wide, along the migrating edge (limited by dotted line in A). Intensity labelling
signal was calculated using the LASAF Leica software and expressed in intensity/mm
2 (results from 3 independent experiments). p,0.05 for (*)
control+rosuvastatin vs control and (**) agLDL+rosuvastatin vs agLDL.
doi:10.1371/journal.pone.0038935.g004
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TM XRS system using the Quantity-One 1-D analysis
software (Bio-Rad).
Immunofluorescence and confocal microscopy
Cells were fixed with 4% paraformaldehyde, permeabilized
(0.5% Tween-PBS), and blocked with 1% bovine serum albumin
(BSA). P-MRLC was detected with a rabbit polyclonal antibody
(Santa Cruz) and RhoA with a monoclonal-antibody (Santa Cruz).
The secondary antibodies were Alexa Fluor-488 conjugated anti-
rabbit or anti-mouse antibodies (Molecular Probes dilution 1/100).
Negative controls of primary and secondary antibody staining
were run with each set of experiments. F-actin was stained with
Alexa Fluor-633 phalloidin (Molecular Probe) and nuclear
counterstain with Hoechst (Molecular Probes). Labelled cells were
examined in a Leica inverted fluorescence confocal microscope
(Leica TCS SP2-AOBS). Fluorescent images were acquired in a
scan format of 102461024 pixels at intervals of 0,1 mm (20 slides)
and processed with the TCS-AOBS software (Leica). Maximal
intensity projection values were calculated using the LASAF Leica
Software and given as AU/mm
2.
RhoA Activity Assay
Levels of active RhoA were measured in cytosol extracts and in
total cell lysate with a RhoA activation assay kit (BK036,
Cytoskeleton) based in a pull-down technique, following the
manufacturer’s instructions. Briefly, VSMC were starved 24 hours
Figure 5. Increased levels of RhoA-GTP in cytosol of human
VSMC exposed to agLDL in the presence of rosuvastatin. (A)
Antigen (total RhoA) and active RhoA (RhoA-GTP) levels in total cell
lysates and cytosol extracts of VSMC treated without/with rosuvastatin
in absence/presence of nLDL and agLDL for 24 hours. Levels of active
RhoA were determined by a pull down assay with GST-rothekin. Note
the strong band for active RhoA in the cytosol of rosuvastatin treated
cells. (B) Total and active RhoA levels in the cytosol fraction of VSMC
treated without and with rosuvastatin +/210 mM geranyl-geraniol
pyrophosphate (GGPP), in the absence and presence of nLDL and
agLDL for 24 hours. (C) Western blot analysis for ROCK antigen levels in
cytosol extracts of cells exposed for 24 hours to agLDL in the absence
and presence of rosuvastatin. C denotes the control non treated group.
doi:10.1371/journal.pone.0038935.g005
Figure 6. Rosuvastatin induced MRLC-phosphorylation in
agLDL-VSMC is dependent on the activity of the RhoA/ROCK
signaling pathway. VSMC incubated without/with agLDL, in the
absence/presence of rosuvastatin analyzed by western blot for (A)P -
MRLC in agLDL-VSMC incubated with rosuvastatin in the absence/
presence of inhibitors for MLC-Phosphatase (Y27632) and MLCK (ML9).
Bar diagram expresses mean6SEM of 3 independent experiments.
*P,0.05 (Mann Whitney test) vs agLDL. # P,0.05 (Mann Whitney test)
vs agLDL+rosuvastatin group. (B) phosphorylated PAK (p21-activated
kinase) levels in VSMC exposed to agLDL in the absence/presence of
rosuvastatin. Bar diagram represent the mean6SEM of 3 independent
experiments. P,0.05 (Mann Whitney test), * vs control group.
doi:10.1371/journal.pone.0038935.g006
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(cytosol extract) or with lysis buffer provided by the RhoA
activation assay kit. Protein concentration was determined
immediately (Precision Red Advanced Protein Assay Reagent,
ADV02, Cytoskeleton) and equal amount of extracts were
incubated with GST-Rhotekin sepharose beads in order to pull
down active RhoA. Pulled down beads were washed twice and
resuspended in Laemmli sample buffer. The complete pulled
down sample, containing only active RhoA, was analyzed by
western blot, as described above.
Statistical analysis
Results are presented as mean6SEM and the number of
experiments is shown in every case (see figure legends). Statistical
differences between groups were analyzed by parametric tests as
T-Student, one-way analysis of variance (ANOVA) or two-way
ANOVA, followed by the Fisher’s PLSD test for group differences
or by non-parametric tests (Kruskal Wallis or Mann-Whitney), as
indicated. P value of 0.05 or less was considered significant.
Results
Rosuvastatin prevents LDL-induced impairment of VSMC-
migration
Our previous studies have shown that agLDL hamper mobility
of human coronary VSMC [18–19]. Here, treatment of VSMC
with 10 mM rosuvastatin prevented LDL-induced impairment in
migration kinetics and repaired the cell-depleted areas (Fig. 1A).
Differences in cell migration due to treatment with rosuvastatin
were already observed 2 hour after wounding (Fig. 1B, Table S1).
Figure 7. Rosuvastatin induced actin-cytoskeleton reorganization, cell adhesion and migration in agLDL-VSMC is dependent on the
RhoA/ROCK signaling pathway. agLDL-VSMC incubated with rosuvastatin in absence/presence of inhibitors for ROCK (Y27632) or MLCK (ML9)
were analyzed for (A) filamentous actin organization during cell attachment. Note that rosuvastatin-promoted filamentous actin organization in LDL-
VSMC was prevented by Y27632 (B) cell attachment (expressed as percentage of the control group) (*) vs agLDL and (#) vs agLDL+ rosuvastatin
group, p,0.01 (Mann Whitney test). (C) wound repairing (*) vs agLDL p,0.01 (Mann Whitney test) and (#) vs agLDL+ rosuvastatin group, p,0.01
(Mann Whitney test). In B and C, bar diagrams represent the mean6SEM of 3 independent experiments.
doi:10.1371/journal.pone.0038935.g007
Figure 8. Scheme for signaling pathways regulating MRLC-
phosphorylation in human VSMC. Potential mechanisms
involving agLDL and rosuvastatin effects are indicated. MRLC:
Myosin regulatory light chain; MLCK: Myosin light chain kinase. MLC-P:
Myosin light chain phosphatase; ROCK: Rho-associated protein kinase;
PAK: p21-activated protein kinase. RhoA: Small G proteins; agLDL:
aggregated low density lipoproteins.
doi:10.1371/journal.pone.0038935.g008
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2/hour) were significantly
higher in cells treated with rosuvastatin than in cells incubated
with LDL alone (P,0.01 for both nLDL and agLDL). In contrast,
rosuvastatin did not affect wound repair kinetics in the control
non-LDL treated group (Fig. 1C; P=NS for control vs
control+rosuvastatin group).
As shown in Fig. 2A, the effect of rosuvastatin on migration of
VSMC exposed to LDL (LDL-VSMC) was dose-dependent (2.5 to
10 mM). Thus, rosuvastatin at 10 mM, concentration that corre-
sponds to the blood concentration in patients treated with high
therapeutic-doses (40 mg), restored to control levels the VSMC
migration that was interfered by LDL. A non-statistically
significant increase with respect to 10 mM was found with
40 mM rosuvastatin, concentration above the therapeutic range.
Simvastatin elicited a similar effect at a lower concentration
according to its lipophilic structure. The effect of rosuvastatin in
restoring VSMC migration kinetics was already evident at
4 hours. Additionally, in a set of experiments, VSMC were
lipid-loaded (100 mg/mL agLDL for 8 hours [40], Fig. 2B) and
then rosuvastatin (10 mM) added for an additional 8 hour-period
before wounding. Rosuvastatin restored the migration capacity of
VSMC to similar level when treating both lipid-loaded and lipid-
unloaded cells (Fig. 2C).
The effects of rosuvastatin on the recovery of wound repair
function in lipid-loaded-VSMC were not caused by cell prolifer-
ation. Indeed, a cell [3H]thymidine incorporation assay demon-
strated, as expected, that rosuvastatin (10 mM) significantly
reduced (about 80%) proliferation in lipid-loaded VSMC (Table
S2).
Rosuvastatin reverts the changes induced by LDL on the
proteome of MRLC in human coronary VSMC
2-DE and MALDI-TOF techniques were used to compare the
proteomic pattern of the non sarcomeric-MRLC isoforms MRLC-
2 (Swiss-Prot number: O14950; observed pI 5.1, observed MW
21.5 kDa) and MRLC-3 (Swiss-Prot number: P19105; observed pI
5.0, observed MW 22.2 kDa) in human VSMC treated with/
without rosuvastatin during exposure to native/aggregated LDL
(Fig. 3).
MRLC isoforms appeared as a double spot of different pI
(MRLC-2: spots 1,2; MRLC-3: spots 3,4; Fig. 3A), which were
related to different phosphorylation states. For each MRLC-
isoform, the ratio between the intensity level of the spot with lower
pI (more phosphorylated forms) and this with higher pI (less
phosphorylated forms) was calculated. Treatment of VSMC with
rosuvastatin reverted dephosphorylation induced by LDL in
MRLC-3 and MRLC-2. The effect was markedly evident for
the agLDL-treated group (Fig. 3B).
Western blot analysis of agLDL-VSMC treated with different
rosuvastatin concentrations revealed a progressive increase in P-
MRLC compared to untreated cells (Fig. 3C), being the increase
already evident with the lowest concentration of rosuvastatin
(2.5 mM). The highest concentration of rosuvastatin (10 mM)
increased levels of P-MRLC to 90% of the control group (without
agLDL).
Rosuvastatin increases P-MRLC levels at the migration
front of agLDL-treated VSMC
We have also examined the effect of rosuvastatin on the
subcellular distribution of P-MRLC by confocal microscopy (Fig.
S1). Migrating agLDL-VSMC treated with rosuvastatin shows a P-
MRLC labelling signal intensity similar to the control group.
Contrarily, the P-MRLC labelling that is very weak at the border
of the wounded area in agLDL treated VSMC, shows a significant
increase in presence of rosuvastatin. Rosuvastatin did not show
any effect on the P-MRLC in control VSMC migrating into the
wounded area.
Effect of rosuvastatin on the subcellular distribution of
RhoA in human VSMC
Because HMG-CoA reductase inhibitors have shown to
regulate isoprenylation of small GTP-binding proteins, we
analyzed subcellular RhoA levels in cytosol, cytoskeleton-associ-
ated and membrane fractions in the lipid loaded VSMC (Fig. S2).
Rosuvastatin treatment significantly increased RhoA protein levels
in the cytosol of the VSMC (.1.5–2.0fold, p,0.05), while weakly
decreased RhoA in the cytoskeleton associated fraction. RhoA
levels were markedly lower in the membrane fraction of
rosuvastatin treated cells (.8fold decrease, p,0.01).
By confocal microscopy analysis, migrating VSMC consistently
showed high RhoA levels at the leading edge of the cells, either in
the presence or absence of agLDL (Fig. 4A). Rosuvastatin
significantly increased RhoA labelling at the migrating front edge
(compare Fig. 4B-a and 4B-b with 4B-c and 4A-d). Taking as
reference the bulk of RhoA labelling in the control group
(Figure 4A), we have defined a 15 mm wide area along the border
of the wound (boundary marked by dot lines in Fig. 4B) to quantify
the effect of rosuvastatin on the RhoA-level in the migrating
VSMC. As shown in Fig. 4C, rosuvastatin induced .2.5fold
increase of RhoA either in control and LDL-treated cells (P,0.05
both for control and agLDL-VSMC).
Effect of rosuvastatin on RhoA-GTP levels
Levels of RhoA-GTP (active RhoA) were analyzed by a pull
down assay with GST-rothekin in total cell lysates and cytosol
extracts (Fig. 5A). RhoA-GTP was detected in the total cell lysates
of both control and LDL-treated VSMC, but never in the cytosolic
fraction of these cells. Levels of RhoA-GTP were significantly
increased when cells were treated with rosuvastatin. RhoA-GTP
levels increased both in total cell lysates and in the cell cytosol-
fraction (Fig. 5A). There was no increase in RhoA-GTP in the
cytosol of cells coincubated with rosuvastatin and 10 mM geranyl-
geraniol pyrophosphate (GGPP) (Fig. 5B). Besides, the level of
cytosolic ROCK, the major downstream target of active RhoA,
was 2.5fold increased (P,0.01) in agLDL-VSMC treated
rosuvastatin (Fig. 5C).
By 2-DE we identified the p50RhoGAP (Q07960, pI 5.9, MW
50 kDa), a member of the GTPase activating protein family that
catalyzes inactivation of RhoA. This protein was significantly
overexpressed by agLDL-loading of VSMC (mean6SE intensity
level in control vs agLDL group: 0.2860.01 vs 0.4160.05 AU,
P=0.03, Fig. S3). Treatment with rosuvastatin decreased
p50RhoGAP in agLDL-VSMC to levels detected in control cells
(agLDL+rosuvastatin: 0.2760.01 AU, P=0.02 vs agLDL).
Rosuvastatin-induced MRLC-phosphorylation,
cytoskeleton reorganization, cell adhesion and migration
in agLDL-VSMC is dependent on ROCK-signaling
We next explored whether the RhoA-downstream pathway was
involved in the effect of rosuvastatin on the cytoskeleton dynamics
in agLDL-VSMC. MRLC-phosphorylation is mainly influenced
by the opposing activities of MLC-kinase (MLCK) and MLC-
phosphatase (MLC-P), which in turn are regulated by p21-
activated protein kinase (PAK-1) and Rho-dependent kinase
(ROCK) [42–43].
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(10 mM) abolished the increase in P-MRLC induced by rosuvas-
tatin in agLDL-VSMC (phosphorylation ratio agLDL: 0.3460.00;
agLDL+rosuvastatin: 0.9260.01, agLDL+rosuvastatin+Y27632:
0.3360.04; P,0.01). Addition of the MLC-kinase inhibitor ML-9
induced a non-significant reduction of P-MRLC (agLDL+rosu-
vastatin+ML9: 0.7060.16; P=NS vs agLDL+rosuvastatin). The
levels of phosphorylated-PAK1 (P-PAK1) were 2fold increased
(p,0.05) in agLDL- VSMC with respect to control cells, an effect
not reversed by rosuvastatin (10 mM) (Fig. 6B).
In a subset of experiments, VSMC were incubated with agLDL
and treated with/without rosuvastatin for 16 hours, and then were
seeded and allowed to attach on glass plates for 3 hours. Confocal
analysis of actin fibres labelled with Alexa Fluor-633 phalloidin
(Fig. 7A) demonstrated that rosuvastatin strongly promoted
filamentous actin organization in LDL-treated VSMC, whereas
co-incubation with 10 mM Y27632 prevented the effect of
rosuvastatin. Three hours after seeding, 7363% of the plated
agLDL-VSMC were attached in the presence of rosuvastatin
whereas only 3064% in the absence of rosuvastatin (P,0.01)
(Fig. 7B). Co-incubation of rosuvastatin with 10 mM Y27632
decreased cell attachment to the level of the agLDL-VSMC
(22610%; P,0.01 vs LDL+rosuvastatin group; P=NS vs LDL-
group).
The ROCK inhibitor Y27632 consistently reduced the revers-
ing effect of rosuvastatin on LDL-induced impairment in cell
migration (Fig. 7C). Thus, when agLDL treated cells were co-
incubated with Y27362 and rosuvastatin the percentage of wound
coverage did not differ significantly from the basal levels observed
in the absence of rosuvastatin. In addition, Y27362 retarded the
induction of migration (2 hours) during an in vitro wound healing
assay in control VSMC, but no significant difference was seen at
longer times. Y27362 had also no effect when VSMC were treated
only with rosuvastatin.
Discussion
Atherosclerotic plaques with large lipid cores and paucity of
VSMC have an increased risk of rupture. We have recently
demonstrated that LDL impair VSMC migration kinetics and
induce changes in cytoskeleton proteins [18–19], mechanisms by
which LDL could contribute to the relative loss of human VSMC
in vulnerable plaques. The role of infiltrated LDL in vascular
remodelling and repair is a key issue to understand progression of
atherosclerosis. Modified LDL are found within the diseased vessel
in close contact with smooth muscle cells. These infiltrated LDL
aggregate and accumulate by binding to extracellular matrix
proteoglycans [9,11,13] becoming targets for oxidation, glycation,
and other enzymatic modifications. Therefore, aggregation is the
initial modification suffered by infiltrated LDL affecting VSMC
function and phenotype. Indeed, in addition to cytoeskeleton
protein modifications, LDL downregulate expression of LDLR
whereas upregulate expression of LRP1, a receptor for agLDL in
VSMC [14–15]. Thus, LRP1 by internalizing significant amounts
of cholesteryl esters from agLDL contributes to the transformation
of VSMC into ‘‘foam cell-like’’ cells [15–17]. Overexpression of
LRP1 has been found in atherosclerotic plaques in animal models
and in human plaques of increasing severity [44–46].
HMG-CoA reductase inhibitors have shown to reduce clinical
cardiovascular disease presentation [23–24]. Among them,
rosuvastatin, the latest introduced, has shown efficacy in primary
presentation [26] and regression or halt of disease burden [27,47].
Several studies have shown that statins favourably alter the
fibromuscular composition of the plaques both in hyperlipidaemic
ApoE
2/2 mice with increased collagen content and increased
SMC-a-actin [34–35] and human carotid plaques [33].
In this study, we aimed at investigating the mechanisms by
which rosuvastatin exert plaque remodelling effects and report that
rosuvastatin elicits a counteracting regulation of the impairing
effects of LDL on VSMC function and migration kinetics.
Here, we report for the first time that rosuvastatin prevents in a
dose-dependent manner the agLDL-induced dephosphorylation of
MRLC and the agLDL-detrimental effects on actin fiber
formation. Additionally, rosuvastatin affects intracellular localiza-
tion of phosphorylated-MRLC that is found concentrated at the
front edge of the migrating cells in the treated VSMC.
Phosphorylated-MRLC activates myosin II through its ATPase
motor domain, a critical regulator of cytokinesis and as
consequence of cell migration [8,29].
Rho GTPases are key regulators of cytoskeleton dynamics in a
wide variety of morphogenetic events, including cell migration
[48–49]. Earlier studies in migrating cells had linked Rac1 to the
protrusion of the leading edge and RhoA to the contractility
control at the back of the cell [50]. However, as shown here
recently RhoA has been reported to accumulate at the front of
migrating cells. To this respect, a Rab13 dependent trafficking of
RhoA from the junctions to the leading edges has been shown in
migrating endothelial cells [51]. Besides, active RhoA has been
detected in lamellipodia and filopodia of transendothelial migrat-
ing T cells where it was involved via mDIA or ROCK signalling in
regulation of actin-myosin-mediated protrusion and retraction
events at the leading edge [52]. Additionally, a spatio-temporal
dynamic process coordinated with other Rho GTPases as Rac and
Cdc42 has been also reported [49].
HMG-CoA reductase inhibitors block the synthesis of farnesyl
pyrophosphate (FPPP) and geranylgeranyl pyrophosphate (GGPP)
isoprenoids and thereby disrupt posttranslational isoprenylation
and intracellular translocation from cytoplasm to membrane of
isoprenylated proteins involved in cell signalling, such as the
members of the Rho family [53]. We have recently demonstrated
that simvastatin abrogates agLDL-induced translocation of RhoA
to cell membrane in VSMC [54]. Here, we further report that
rosuvastatin leads to a highly significant increase in functional
GTP-RhoA in the cytosol of VSMC, along with a several-fold
decrease in the amount of RhoA partitioning in the membrane
compartment. These new findings in VSMC are consistent with
those of previous studies in monocytes, HEL cells and endothelial
cells showing that statins promote Rho-GTP binding and
activation [55–56]. Besides, we report a significant increase of
RhoA protein at the front edge of migrating LDL-loaded-VSMC
in response to rosuvastatin. All together, our results suggest that
anchoring of active RhoA in the cell membrane is not required for
the increase in cell motility induced by rosuvastatin in LDL-loaded
cells. The functional relevance of this finding is underscored by
studies showing that unprenylated G-proteins are also biologically
active [55,57–58].
Further studies are needed to determine the mechanism
underlying rosuvastatin-mediated cytosolic RhoA activation.
One potential explanation is that HMG-CoA reductase inhibitors
disrupt the interaction of small G-proteins with its negative
regulator RhoGDI (Rho guanine nucleotide dissociation inhibitor)
[56], as they do with GTPase-activating proteins (GAPs) that
accelerate GTP hydrolysis. These interactions depend on protein
isoprenylation [59]. Interestingly, in our study, supplementation of
VSMC cultures with GGPP prevented rosuvastatin-induced
RhoA-GTP increase in the cellular cytosol. Beside, we observed
higher p51GAP levels in LDL-loaded-VSMC in the absence than
in the presence of rosuvastatin.
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responses linked to actin dynamics [60]. RhoA-GTP by binding to
the Rho-binding domain (RBD) of ROCK disrupts the interaction
between the catalytic N-terminal and the inhibitory C-terminal
regions of the enzyme, stimulating in turn the phosphotransferase
activity of ROCK [61]. Thus, RhoA regulates MRLC-phosphor-
ylation through its downstream effector ROCK and through
MLC-phosphatase. In addition, ROCK may also phosphorylate
Ser19 in MRLC, the same residue that is phosphorylated by MLC
kinase (MLCK) [43]. In LDL-loaded-VSMC, ROCK inhibition
completely reverted rosuvastatin induced MRLC-phosphoryla-
tion, whereas MLC-kinase (MLCK) inhibition did not induced a
significant effect. Taken together, these results indicate that
rosuvastatin induces MRLC-phosphorylation, enhances cytoskel-
eton organization and promotes cell adhesion and migration of
LDL-loaded-VSMC through a mechanism involving activation of
the RhoA/ROCK downstream pathway.
MLCK activity is inhibited by phosphorylated p21-activated
kinase (P-PAK) [42]. Rosuvastatin did not revert the increase in
phosphorylated PAK induced by agLDL, thus emphasizing the
relevance of the ROCK signalling pathway in MRLC-phosphor-
ylation. Thus, we propose that agLDL induced MRLC-dephos-
phorylation in VSMC is linked to high levels of P-PAK and to a
low MLCK-activity, whereas rosuvastatin counteracts the agLDL
effect on P-MRLC by a mechanism that mainly depends on the
increase of cytosolic RhoA-GTP and its target ROCK, which in
turn blocks MLC-phophatase activity and activates MRLC-
phosphorylation (Fig. 8). In control cells, without LDL, there is
a redundancy in the mechanisms involved in MRLC-phosphor-
ylation that overcome the effect of rosuvastatin during cell
migration. Indeed, rosuvastatin, in the absence of LDL, does not
induce migration in VSMC, in agreement with the inhibitory
effect in motility attributed by others to rosuvastatin in absence of
LDL [62–63]. Moreover, rosuvastatin might affect VSMC
migration through additional mechanisms directly involving
activation/inhibition of other small G-proteins, which will require
future studies.
In summary, current imaging methods in clinical studies [27]
have shown that rosuvastatin reduces atherosclerotic plaque
burden and the vulnerability of the plaques. Here, we demonstrate
that these effects of rosuvastatin could be mediated by counter-
acting the impairing effects of LDL in MRLC phosphorylation
and cell migration/repair function of lipid-loaded-VSMC. These
mechanisms may strongly contribute to stabilize lipid-rich
atherosclerotic plaques.
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Table S1 Effect of rosuvastatin treatment on regenera-
tion of cell depleted areas (% of wounded area at time 0)
by coronary derived human VSMC at different time
periods after wounding.
(DOC)
Table S2 Effect of rosuvastatin (10 mM) on levels of
[3H]thymidine incorporation in human VSMC exposed
to 100 mg/mL nLDL or agLDL.
(DOC)
Figure S1 Effect of rosuvastatin on subcellular localiza-
tion of phosphorylated MRLC in migrating VSMC
during wound healing. Confocal microscopy of migrating cells
(10%FCS-stimulated), 4 hours after wounding. Human coronary
VSMC treated as shown for 16 hours. Cells were labelled for P-
MRLC (Alexa Fluor 488-conjugated, signal in green) and F-actin
(Alexa-Fluor 633 conjugated phalloidin, signal in red).
(TIF)
Figure S2 Increase of RhoA levels upon rosuvastatin
treatment in the cytosol of human VSMC. RhoA and b-
actin in cytosol, cytoskeleton-membrane and membrane extracts
of VSMC with/without LDL and treatment with rosuvastatin or
vehicle for 24 hours. The histograms show results expressed as %
of the controls after normalization for b-actin. Results are given as
mean6SEM of 3 independent experiments.
(TIF)
Figure S3 Rosuvastatin decreases p50RhoGAP level in
LDL-treated VSMC. Representative 2-DE gel of the urea/
detergent-soluble fraction of human VSMC. Enlarged images
correspond to the gel area where p50RhoGAP (pI 5.9, MW
50 kDa) was detected. Rosuvastatin markedly decreases the
labelling signal for p50RhoGAP (agLDL+rosuvastatin) in VSMC
treated with agLDL.
(TIF)
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